SCHEDULE: BlackRock Discloses 5.5% Passive Stake in Amylyx Pharmaceuticals
Beneficial Ownership Report
BlackRock, Inc. has reported a passive beneficial ownership of 5.5% of Amylyx Pharmaceuticals, Inc.'s common stock, totaling 4,917,501 shares.
Summary
- BlackRock, Inc. has filed a Schedule 13G, indicating its beneficial ownership in Amylyx Pharmaceuticals, Inc.
- BlackRock, Inc. holds an aggregate of 4,917,501 shares of Amylyx Pharmaceuticals, Inc. common stock.
- This ownership represents 5.5% of the total outstanding common stock of Amylyx Pharmaceuticals, Inc.
- BlackRock, Inc. has sole voting power over 4,827,647 shares and sole dispositive power over 4,917,501 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- Several BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Fund Advisors, are identified as entities through which the beneficial ownership is held, with at least one beneficially owning 5% or greater of the outstanding shares.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing disclosing a passive ownership stake by a large institutional investor. It does not contain positive or negative news about the issuer's performance or outlook, but the presence of a major investor like BlackRock can be seen as a neutral to slightly positive signal of institutional interest.
Future Outlook
NA
Industry Context
This filing is a routine disclosure by a major institutional asset manager, BlackRock, Inc., indicating a passive investment stake in a pharmaceutical company. Such disclosures are common and reflect portfolio management activities rather than specific strategic moves related to the issuer's industry position.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional ownership stake, which can influence market perception and liquidity.
- Regulatory Authorities: Fulfills SEC disclosure requirements for beneficial ownership, ensuring market transparency.
Key Dates
| Date | Description |
|---|---|
| 2025-01-21 | Date of Power of Attorney execution by BlackRock, Inc. |
| 2025-06-30 | Date of event which requires the filing of this statement (beneficial ownership threshold crossed or reporting period end). |
| 2025-07-17 | Date of Schedule 13G filing and signature by BlackRock, Inc. |
Keywords
BlackRock, Amylyx Pharmaceuticals, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Passive Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.